IMFINZI (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer Pharmaceutical Investing
BioCryst’s BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema Pharmaceutical Investing
Theratechnologies Announces Agreement With AIDS Drug Assistance Program (ADAP) for Trogarzo and EGRIFTA Pharmaceutical Investing
